Merck (MRK) Amortizatization of Intangibles (2020 - 2026)
Merck (MRK) reported Amortizatization of Intangibles of $931.0 million for Q1 2026, up 55.95% year-over-year from $597.0 million in Q1 2025, and down 4.32% on a QoQ basis from $973.0 million in Q4 2025.
Merck (MRK) has 7 years of Amortizatization of Intangibles data on file, last reported at $931.0 million in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 55.95% year-over-year to $931.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 24.18% YoY) and the FY2025 annual result came in at $2.8 billion, up 16.62% from the prior year.
- Amortizatization of Intangibles fell to $931.0 million in Q1 2026 per MRK's latest filing, from $973.0 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $973.0 million in Q4 2025 and bottomed at $460.0 million in Q3 2022.
- The 5-year median for Amortizatization of Intangibles is $597.0 million (2025), against an average of $602.8 million.
- The widest annual swing landed in 2023, when Amortizatization of Intangibles slipped 22.32%; it then jumped 55.95% in 2026.
- Tracing MRK's Amortizatization of Intangibles over 5 years: stood at $462.0 million in 2022, then changed by 0.0% to $462.0 million in 2023, then surged by 46.1% to $675.0 million in 2024, then soared by 44.15% to $973.0 million in 2025, then fell by 4.32% to $931.0 million in 2026.
- Per Business Quant, the three latest MRK Amortizatization of Intangibles figures stand at $931.0 million (Q1 2026), $973.0 million (Q4 2025), and $623.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 1.70 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 931.00 Mn |
| Mar 31, 2026 | 931.00 Mn |
| Dec 31, 2025 | 973.00 Mn |
| Dec 31, 2025 | 973.00 Mn |
| Sep 30, 2025 | 623.00 Mn |
| Sep 30, 2025 | 623.00 Mn |
| Jun 30, 2025 | 601.00 Mn |
| Jun 30, 2025 | 601.00 Mn |
| Mar 31, 2025 | 597.00 Mn |
| Mar 31, 2025 | 597.00 Mn |
| Dec 31, 2024 | 675.00 Mn |
| Dec 31, 2024 | 675.00 Mn |
| Sep 30, 2024 | 633.00 Mn |
| Sep 30, 2024 | 633.00 Mn |
| Jun 30, 2024 | 614.00 Mn |
| Jun 30, 2024 | 614.00 Mn |
| Mar 31, 2024 | 473.00 Mn |
| Mar 31, 2024 | 473.00 Mn |
| Dec 31, 2023 | 462.00 Mn |
| Dec 31, 2023 | 462.00 Mn |
| Sep 30, 2023 | 562.00 Mn |
| Sep 30, 2023 | 562.00 Mn |
| Jun 30, 2023 | 477.00 Mn |
| Jun 30, 2023 | 477.00 Mn |
| Mar 31, 2023 | 543.00 Mn |
| Mar 31, 2023 | 543.00 Mn |
| Dec 31, 2022 | 462.00 Mn |
| Dec 31, 2022 | 462.00 Mn |
| Sep 30, 2022 | 460.00 Mn |
| Sep 30, 2022 | 460.00 Mn |
| Jun 30, 2022 | 463.00 Mn |
| Jun 30, 2022 | 463.00 Mn |
| Mar 31, 2022 | 699.00 Mn |
| Mar 31, 2022 | 699.00 Mn |
| Dec 31, 2021 | 405.00 Mn |
| Dec 31, 2021 | 405.00 Mn |
| Sep 30, 2021 | 360.00 Mn |
| Sep 30, 2021 | 360.00 Mn |
| Jun 30, 2021 | 357.00 Mn |
| Jun 30, 2021 | 357.00 Mn |
| Mar 31, 2021 | 514.00 Mn |
| Mar 31, 2021 | 514.00 Mn |
| Dec 31, 2020 | 424.00 Mn |
| Dec 31, 2020 | 424.00 Mn |
| Sep 30, 2020 | 406.00 Mn |
| Sep 30, 2020 | 406.00 Mn |
| Jun 30, 2020 | 599.00 Mn |
| Jun 30, 2020 | 599.00 Mn |
| Mar 31, 2020 | 410.00 Mn |
| Mar 31, 2020 | 410.00 Mn |